iSERA Lifesciences Ltd
₹ 144
0.00%
30 Sep
- close price
- Market Cap ₹ 121 Cr.
- Current Price ₹ 144
- High / Low ₹ 151 / 7.99
- Stock P/E
- Book Value ₹ 9.81
- Dividend Yield 0.00 %
- ROCE 5.95 %
- ROE 6.38 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 14.7 times its book value
- Company has high debtors of 337 days.
- Promoter holding has decreased over last 3 years: -41.4%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.90 | 25.50 | 21.36 | 28.92 | 12.30 | 2.13 | 2.13 | 0.00 | 0.00 | 0.00 | 0.27 | 1.30 | 1.35 | |
| 10.28 | 25.14 | 20.92 | 28.46 | 11.98 | 2.19 | 0.19 | 0.11 | 0.11 | 0.09 | 0.13 | 1.03 | 1.40 | |
| Operating Profit | 0.62 | 0.36 | 0.44 | 0.46 | 0.32 | -0.06 | 1.94 | -0.11 | -0.11 | -0.09 | 0.14 | 0.27 | -0.05 |
| OPM % | 5.69% | 1.41% | 2.06% | 1.59% | 2.60% | -2.82% | 91.08% | 51.85% | 20.77% | -3.70% | |||
| 0.00 | -12.61 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.07 | |
| Interest | 0.00 | 0.16 | 0.20 | 0.27 | 0.23 | 0.22 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.50 | 0.08 | 0.21 | 0.15 | 0.08 | 0.12 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.12 | -12.49 | 0.03 | 0.04 | 0.01 | -0.40 | 1.80 | -0.11 | -0.11 | -0.09 | 0.14 | 0.34 | 0.02 |
| Tax % | 0.00% | 0.40% | 100.00% | 25.00% | 200.00% | 5.00% | 1.11% | 0.00% | 0.00% | 0.00% | 14.29% | 23.53% | |
| 0.12 | -12.54 | 0.00 | 0.04 | -0.02 | -0.42 | 1.78 | -0.11 | -0.11 | -0.09 | 0.12 | 0.26 | -0.06 | |
| EPS in Rs | 0.00 | -0.46 | 0.00 | 0.00 | -0.00 | -0.02 | 0.06 | -0.00 | -0.00 | -0.11 | 0.14 | 0.31 | -0.07 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -26% |
| 5 Years: | -9% |
| 3 Years: | % |
| TTM: | 381% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 39% |
| 5 Years: | -32% |
| 3 Years: | 63% |
| TTM: | -146% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 41% |
| 5 Years: | 170% |
| 3 Years: | 313% |
| 1 Year: | 1589% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 6% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10.60 | 10.60 | 10.60 | 10.60 | 10.60 | 10.60 | 10.60 | 0.30 | 0.30 | 0.32 | 0.32 | 8.41 |
| Reserves | 2.44 | -10.10 | -10.09 | -10.05 | -10.07 | -10.49 | -10.71 | -0.31 | -0.42 | -0.54 | -0.42 | -0.16 |
| 4.97 | 6.15 | 6.83 | 7.49 | 7.53 | 6.56 | 2.02 | 0.00 | 0.13 | 0.18 | 1.61 | 1.66 | |
| 2.54 | 4.61 | 5.57 | 8.19 | 4.12 | 3.81 | 2.59 | 0.02 | 0.04 | 0.10 | 0.05 | 0.65 | |
| Total Liabilities | 20.55 | 11.26 | 12.91 | 16.23 | 12.18 | 10.48 | 4.50 | 0.01 | 0.05 | 0.06 | 1.56 | 10.56 |
| 6.65 | 0.48 | 0.44 | 0.45 | 0.75 | 0.62 | 0.43 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CWIP | 1.96 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 4.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 7.74 | 10.78 | 12.47 | 15.78 | 11.43 | 9.86 | 4.07 | 0.01 | 0.05 | 0.06 | 1.56 | 10.56 | |
| Total Assets | 20.55 | 11.26 | 12.91 | 16.23 | 12.18 | 10.48 | 4.50 | 0.01 | 0.05 | 0.06 | 1.56 | 10.56 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.50 | 0.81 | -0.63 | -0.51 | 0.34 | 0.97 | 4.45 | -0.30 | -0.12 | -0.06 | -1.40 | -5.35 | |
| -1.16 | -0.40 | -0.16 | -0.16 | -0.38 | 0.00 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | |
| 0.69 | -0.42 | 0.77 | 0.66 | 0.04 | -0.97 | -4.55 | 0.30 | 0.13 | 0.06 | 1.42 | 8.14 | |
| Net Cash Flow | 0.04 | -0.01 | -0.02 | -0.01 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.02 | 2.85 |
| Free Cash Flow | -0.78 | 0.41 | -0.79 | -0.67 | -0.04 | 0.97 | 4.55 | -0.30 | -0.12 | -0.06 | -1.40 | -5.35 |
| CFO/OP | 81% | 225% | -143% | -109% | 112% | -1,650% | 229% | 273% | 109% | 67% | -986% | -1,952% |
Ratios
Standalone / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 192.55 | 122.81 | 174.64 | 177.96 | 297.34 | 1,470.28 | 498.66 | 419.07 | 336.92 | |||
| Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 192.55 | 122.81 | 174.64 | 177.96 | 297.34 | 1,470.28 | 498.66 | 419.07 | 336.92 | |||
| Working Capital Days | 174.46 | 65.13 | 91.59 | 73.58 | 170.33 | 1,041.88 | 260.47 | 351.48 | 224.62 | |||
| ROCE % | 0.68% | 2.27% | 3.29% | 4.03% | 2.98% | -2.44% | 42.42% | -11.58% | 19.05% | 5.95% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Export Turnover (Foreign Exchange Earnings) INR Lakhs |
|
|||||||||
| Number of Subsidiaries count |
||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Allotment
- Board approved allotment of 1.61 crore shares at Rs 48.20 each on October 1, 2026.
-
Board Meeting Outcome for Outcome Of The Board Meeting Of Isera Lifesciences Limited (Formerly Known As Covidh Technologies Limited) (The "Company") Held On October 01, 2026.
- Board approved allotment of 1.61 crore shares via share swap at Rs48.20, raising capital to 2.46 crore shares.
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
- Shareholder Meeting / Postal Ballot-Outcome of AGM
- Closure of Trading Window
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1]
CTL is in the business of providing Information
Technology / Information Technology Enabled Services.